Literature DB >> 27570424

Mechanisms of drug resistance in colon cancer and its therapeutic strategies.

Tao Hu1, Zhen Li1, Chun-Ying Gao1, Chi Hin Cho1.   

Abstract

Drug resistance develops in nearly all patients with colon cancer, leading to a decrease in the therapeutic efficacies of anticancer agents. This review provides an up-to-date summary on over-expression of ATP-binding cassette (ABC) transporters and evasion of apoptosis, two representatives of transport-based and non-transport-based mechanisms of drug resistance, as well as their therapeutic strategies. Different ABC transporters were found to be up-regulated in colon cancer, which can facilitate the efflux of anticancer drugs out of cancer cells and decrease their therapeutic effects. Inhibition of ABC transporters by suppressing their protein expressions or co-administration of modulators has been proven as an effective approach to sensitize drug-resistant cancer cells to anticancer drugs in vitro. On the other hand, evasion of apoptosis observed in drug-resistant cancers also results in drug resistance to anticancer agents, especially to apoptosis inducers. Restoration of apoptotic signals by BH3 mimetics or epidermal growth factor receptor inhibitors and inhibition of cancer cell growth by alternative cell death pathways, such as autophagy, are effective means to treat such resistant cancer types. Given that the drug resistance mechanisms are different among colon cancer patients and may change even in a single patient at different stages, personalized and specific combination therapy is proposed to be more effective and safer for the reversal of drug resistance in clinics.

Entities:  

Keywords:  ATP-binding cassette transporters; Autophagy; Colon cancer; Drug resistance; Evasion of apoptosis

Mesh:

Substances:

Year:  2016        PMID: 27570424      PMCID: PMC4974586          DOI: 10.3748/wjg.v22.i30.6876

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  155 in total

Review 1.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

Review 2.  Mammalian multidrug-resistance proteins (MRPs).

Authors:  Andrew J Slot; Steven V Molinski; Susan P C Cole
Journal:  Essays Biochem       Date:  2011-09-07       Impact factor: 8.000

3.  Reversal of in vitro cellular MRP1 and MRP2 mediated vincristine resistance by the flavonoid myricetin.

Authors:  Jelmer J van Zanden; Anika de Mul; Heleen M Wortelboer; Mustafa Usta; Peter J van Bladeren; Ivonne M C M Rietjens; Nicole H P Cnubben
Journal:  Biochem Pharmacol       Date:  2005-04-13       Impact factor: 5.858

Review 4.  Colorectal cancer.

Authors:  David Cunningham; Wendy Atkin; Heinz-Josef Lenz; Henry T Lynch; Bruce Minsky; Bernard Nordlinger; Naureen Starling
Journal:  Lancet       Date:  2010-03-20       Impact factor: 79.321

Review 5.  Autophagy in atherosclerosis: a cell survival and death phenomenon with therapeutic potential.

Authors:  Wim Martinet; Guido R Y De Meyer
Journal:  Circ Res       Date:  2009-02-13       Impact factor: 17.367

6.  Expression and significance of hypoxia-inducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells.

Authors:  Zhenyu Ding; Li Yang; Xiaodong Xie; Fangwei Xie; Feng Pan; Jianjun Li; Jianming He; Houjie Liang
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-09       Impact factor: 4.553

7.  Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice.

Authors:  Suneet Shukla; Hani Zaher; Anika Hartz; Björn Bauer; Joseph A Ware; Suresh V Ambudkar
Journal:  Pharm Res       Date:  2008-10-09       Impact factor: 4.200

Review 8.  Targeting multidrug resistance in cancer.

Authors:  Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

Review 9.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

10.  Glutathione S-transferase isoenzymes in human tumours and tumour derived cell lines.

Authors:  A D Lewis; L M Forrester; J D Hayes; C J Wareing; J Carmichael; A L Harris; M Mooghen; C R Wolf
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

View more
  80 in total

1.  A novel 5T4-targeting antibody-drug conjugate H6-DM4 exhibits potent therapeutic efficacy in gastrointestinal tumor xenograft models.

Authors:  Ruixue Wang; Qinhuai Lai; Liangze Tang; Yiran Tao; Yuqin Yao; Yu Liu; Ying Lu; Chaoyong Shen; Ran Lu; Chuanwen Fan; Ruirui Zhang; Yuxi Wang; Lin Yu; Tinghan Yang; Yangping Wu; Yujia Peng; Xian Wei; Yuyin Fu; Weirong Lai; Lantu Gou; Jinliang Yang
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

2.  Codelivery of dihydroartemisinin and doxorubicin in mannosylated liposomes for drug-resistant colon cancer therapy.

Authors:  Xue-Jia Kang; Hui-Yuan Wang; Hui-Ge Peng; Bin-Fan Chen; Wen-Yuan Zhang; Ai-Hua Wu; Qin Xu; Yong-Zhuo Huang
Journal:  Acta Pharmacol Sin       Date:  2017-05-08       Impact factor: 6.150

3.  Microscale Mass Spectrometry Analysis of Extracellular Metabolites in Live Multicellular Tumor Spheroids.

Authors:  Mei Sun; Xiang Tian; Zhibo Yang
Journal:  Anal Chem       Date:  2017-08-16       Impact factor: 6.986

4.  Development of a Colorectal Cancer 3D Micro-tumor Construct Platform From Cell Lines and Patient Tumor Biospecimens for Standard-of-Care and Experimental Drug Screening.

Authors:  Steven Forsythe; Naren Mehta; Mahesh Devarasetty; Hemamylammal Sivakumar; William Gmeiner; Shay Soker; Konstantinos Votanopoulos; Aleksander Skardal
Journal:  Ann Biomed Eng       Date:  2019-04-24       Impact factor: 3.934

5.  Apoptotic Effect of Saccharomyces cerevisiae on Human Colon Cancer SW480 Cells by Regulation of Akt/NF-ĸB Signaling Pathway.

Authors:  Sara Shamekhi; Jalal Abdolalizadeh; Alireza Ostadrahimi; Seyyed Abolghasem Mohammadi; Abolfazl Barzegari; Hajie Lotfi; Esat Bonabi; Nosratollah Zarghami
Journal:  Probiotics Antimicrob Proteins       Date:  2020-03       Impact factor: 4.609

6.  Silencing of miR490-3p by H. pylori activates DARPP-32 and induces resistance to gefitinib.

Authors:  Shoumin Zhu; Shayan Khalafi; Zheng Chen; Julio Poveda; Dunfa Peng; Heng Lu; Mohammed Soutto; Jianwen Que; Monica Garcia-Buitrago; Alexander Zaika; Wael El-Rifai
Journal:  Cancer Lett       Date:  2020-07-29       Impact factor: 8.679

7.  Role of HSP27 in the multidrug sensitivity and resistance of colon cancer cells.

Authors:  Zhengyong Liu; Yi Liu; Yupeng Long; Baohua Liu; Xiangfeng Wang
Journal:  Oncol Lett       Date:  2020-01-07       Impact factor: 2.967

8.  Synergistic antitumor effect of 5-fluorouracil and withaferin-A induces endoplasmic reticulum stress-mediated autophagy and apoptosis in colorectal cancer cells.

Authors:  Abdullah M Alnuqaydan; Bilal Rah; Abdulmajeed G Almutary; Shailender Singh Chauhan
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

9.  P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors.

Authors:  Chengqiong Mao; Yan Zhao; Fang Li; Zibo Li; Shaomin Tian; Waldemar Debinski; Xin Ming
Journal:  J Control Release       Date:  2018-08-04       Impact factor: 9.776

10.  Cullin-1 and -2 Protein Expression in Colorectal Cancer: Correlation with Clinicopathological Variables.

Authors:  Othon Michail; Demetrios Moris; Stamatios Theocharis; John Griniatsos
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.